Actavis Group, a generic pharmaceuticals company, has received the FDA approval to market bupropion hydrochloride extended-release tablets 150mg. Distribution of the product has commenced.

 

Bupropion Hydrochloride extended-release tablets, available in 150 and 300mg strength, are the generic equivalent of Wellbutrin XL for the treatment of major depressive disorder.

Doug Boothe, CEO of Actavis in the US, said: "Bupropion XL 150mg, together with 300mg which was launched in August 2008, offers significant value to our customers and patients. This approval also underscores Actavis's emphasis and capability in bringing complex controlled-release products to the marketplace."